{"id":"W4386002608","doi":"10.1016/j.blre.2023.101128","title":"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Takeda Oncology; Genentech; National Institutes of Health; Foundation Medicine; Sierra Oncology; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Daiichi-Sankyo; MacroGenics; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Argenx; Pfizer; Incyte; CTI Biopharma; bluebird bio; Agios Pharmaceuticals; Syndax Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Acceleron; Loxo Oncology; Astex Pharmaceuticals; Leukemia and Lymphoma Society; Daiichi Sankyo Europe; Servier; Gilead Sciences; Jazz Pharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Myelodysplastic syndromes; Medicine; Risk stratification; Risk assessment; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007043561,0.0004282901,0.002076598,0.0004147447,0.0001007442,0.00003424607,0.0006913005,0.0002727958,0.00002842298],"category_scores_gemma":[0.007855359,0.0002432583,0.0006440851,0.0009752179,0.0002955328,0.00005593198,0.0002140828,0.001068333,0.00002714199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005248961,"about_ca_system_score_gemma":0.003259213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003145287,"about_ca_topic_score_gemma":0.00006512105,"domain_scores_codex":[0.9935999,0.001570847,0.002903414,0.0007528362,0.0008704549,0.0003025551],"domain_scores_gemma":[0.9925129,0.002408928,0.003000569,0.001621572,0.0003479866,0.0001079993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008462114,0.00169959,0.005309087,0.103951,0.002198598,0.0001614686,0.0004076939,0.000007838948,0.000536892,0.001148773,0.01657345,0.8671594],"study_design_scores_gemma":[0.001402023,0.0003907598,0.01598101,0.03662555,0.002852035,0.0006806037,0.00003889585,0.0001425137,0.00005114558,0.00007530022,0.9414793,0.0002808209],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01308934,0.963114,0.0001717667,0.001635437,0.0009453958,0.01964111,0.0008552957,0.00004599054,0.0005016966],"genre_scores_gemma":[0.0007464153,0.9917305,0.0007489991,0.00003597522,0.0000625886,0.00220699,0.0002576594,0.00008001459,0.004130843],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9249059,"threshold_uncertainty_score":0.9919786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1103538405615796,"score_gpt":0.4120282487860294,"score_spread":0.3016744082244499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}